湖南景峰医药股份有限公司 | | 资金占用方名 | 占用方与上 | 上市公司核 | 2023 | 年期初 | 2023 年半年 度占用累计 | 2023 年半年 度占用资金 | 2023 年半年 | 2023 | 年半年 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 市公司的关 | 算的会计科 | | 占用资金余 | | | 度偿还累计 | | 期末占用资 | 占用性质 | | | 称 | | | | | 发生金额（不 | 的利息（如 | | | 因 | | | | | 联关系 | 目 | | 额 | 含利息） | 有） | 发生金额 | 金余额 | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | | | | 前控股股东、实际控制人 | | | | | | | | | | | | | 及其附属企业 | ...

Financial Performance - The company's operating revenue for 2022 was ¥840,657,161.99, representing a 3.63% increase from ¥811,183,491.16 in 2021[20] - The net profit attributable to shareholders was -¥128,162,925.43, an improvement of 21.69% compared to -¥163,660,189.96 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥149,721,920.08, showing a significant reduction of 68.63% from -¥477,230,162.44 in 2021[20] - The basic and diluted earnings per share were both -¥0.1457, reflecting a 21.67% improvement from -¥0.186 in 2021[20] - Total assets at the end of 2022 were ¥1,468,474,402.63, a decrease of 18.07% from ¥1,792,299,532.27 at the end of 2021[20] - The net assets attributable to shareholders decreased by 41.93% to ¥177,927,696.16 from ¥306,389,794.75 in 2021[20] - The cash flow from operating activities was ¥123,266,701.34, a slight decrease of 0.46% from ¥123,834,599.70 in 2021[20] - The company reported a significant reduction in non-operating income, with operating revenue after deductions amounting to ¥818,141,263.01[21] Quarterly Performance - In Q1 2022, the company's operating revenue was approximately ¥181.4 million, while in Q4 2022, it increased to approximately ¥228.8 million, showing a growth of about 26% quarter-over-quarter[25] - The net profit attributable to shareholders in Q2 2022 was a loss of approximately ¥14.8 million, which worsened to a loss of approximately ¥98.4 million in Q4 2022, indicating a significant decline in profitability[25] - The cash flow from operating activities in Q2 2022 was approximately ¥55.9 million, but dropped to approximately ¥10.6 million in Q4 2022, reflecting a decrease of about 81%[25] Industry Context - The pharmaceutical industry in China is undergoing significant reforms, with over 300 policies released in 2022 aimed at improving healthcare delivery and drug procurement processes[32] - The company is facing risks related to product bidding failures and is actively working to enhance product categories and accelerate R&D efforts to mitigate these risks[93] - The company anticipates ongoing price reductions in the pharmaceutical market due to stricter healthcare cost controls, which may lead to a decline in average profit margins[94] Product Development and R&D - The company maintains a diverse product pipeline, including unique products in cardiovascular, oncology, and pediatric fields, which are critical for future growth[33] - The company emphasizes self-research and collaborative development in its R&D model, integrating resources across its subsidiaries to enhance innovation and project outcomes[37] - The company aims to expand its product pipeline continuously, with several products already receiving clinical approval or undergoing clinical research[41] - The R&D center aims to establish a leading research and development system, with ongoing projects including the Phase III clinical trial for a new drug and several consistency evaluations for injection products[88] Marketing and Sales Strategy - The sales model is based on a responsibility system for regional sales managers, combining multi-product matrix management, which has significantly improved per capita productivity and strengthened academic promotion efforts[36] - The company has established a marketing network covering all 31 provinces, cities, and autonomous regions in China, enhancing its sales model to include private hospitals and grassroots medical markets[46] - The marketing strategy focuses on deepening market penetration and enhancing brand value through a combination of direct sales and partnerships[89] Financial Management and Governance - The company has not reported any significant discrepancies between financial reports prepared under international and Chinese accounting standards[22] - The company has established strict production management systems and implemented dynamic monitoring of production processes to ensure compliance with GMP standards, resulting in stable and qualified product quality[36] - The company emphasizes transparent information disclosure, adhering to regulations and ensuring timely and accurate reporting[103] - The board of directors operates with a reasonable professional structure and adheres to legal and regulatory requirements[102] Environmental Compliance and Sustainability - The company has established a comprehensive environmental protection compliance framework, adhering to multiple national and local environmental standards[146] - The company is committed to continuous improvement in its environmental performance, aligning with industry best practices and regulatory expectations[153] - The company has implemented various pollution control technologies, including activated carbon adsorption and alkaline liquid absorption, to ensure compliance with environmental standards[164] Employee Management and Compensation - The total number of employees at the end of the reporting period is 645, with 46 in the parent company and 599 in major subsidiaries[129] - The professional composition includes 278 production personnel, 41 sales personnel, 170 technical personnel, 29 financial personnel, and 127 administrative personnel[129] - The company has a differentiated compensation strategy, ensuring competitive salary levels while controlling labor costs[130] Future Outlook and Strategic Initiatives - The company plans to double the number of hospitals covered by its products in the next five years, currently exceeding 10,000 hospitals[47] - The company is exploring new media and e-commerce technologies to enhance market penetration and reach end consumers more effectively[36] - The company plans to enhance its production capabilities by expanding its CDMO business and leveraging existing production lines for various drug formulations[87]

Financial Performance - The company's operating revenue for 2022 was ¥840,657,161.99, representing a 3.63% increase compared to ¥811,183,491.16 in 2021[20] - The net profit attributable to shareholders was -¥128,162,925.43, an improvement of 21.69% from -¥163,660,189.96 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥149,721,920.08, showing a significant reduction of 68.63% from -¥477,230,162.44 in 2021[20] - The basic earnings per share for 2022 was -¥0.1457, which is a 21.67% improvement from -¥0.186 in 2021[20] - Total assets at the end of 2022 were ¥1,468,474,402.63, a decrease of 18.07% from ¥1,792,299,532.27 at the end of 2021[20] - The net assets attributable to shareholders decreased by 41.93% to ¥177,927,696.16 from ¥306,389,794.75 in 2021[20] - The operating cash flow net amount was ¥123,266,701.34, a slight decrease of 0.46% from ¥123,834,599.70 in the previous year[20] - The weighted average return on equity was -52.93%, worsening from -39.18% in 2021[20] Business Operations - The company has maintained its main business focus in the pharmaceutical manufacturing industry, with no significant changes reported in its business operations[33] - The product pipeline includes unique offerings in various therapeutic areas, such as cardiovascular, oncology, and anti-infection, with several products being exclusive to the company[33] - The company is actively involved in research and development of biopharmaceutical technologies and has a diverse range of products across multiple medical fields[33] - The company has implemented a procurement model focused on risk control, cost minimization, and quality assurance to enhance operational efficiency[34] - The company has over 20 production lines certified by GMP, covering various dosage forms including large and small volume injections, freeze-dried powder injections, and oral preparations[39] Market and Sales Strategy - The company emphasizes a sales model that combines self-operated teams with outsourcing and agency partnerships, enhancing academic marketing efforts[36] - The company has established a strong market presence in the orthopedic field, being the exclusive selected supplier in the Southwest Five Provinces for sodium hyaluronate injections[42] - In the oncology sector, the company secured the first position in the national volume-based procurement for irinotecan injections in several regions including Shanghai and Jiangsu[42] - The company is actively exploring new media and e-commerce technologies for market expansion, aiming to penetrate deeper into the terminal market[36] Research and Development - The company has a robust R&D model that integrates self-research and collaborative development, focusing on key areas for rapid breakthroughs[37] - The company aims to expand its product pipeline continuously, with several products already in clinical trials or having received clinical approval[41] - The company has achieved significant progress in the generic drug sector, with multiple products, including injection forms of gemcitabine and irinotecan, successfully passing consistency evaluation registration[44] - The company is focusing on cost reduction and efficiency improvement by streamlining its workforce and enhancing performance assessments of subsidiaries[48] Environmental Compliance - The company has established a comprehensive pollution control system to manage and treat emissions effectively, ensuring environmental compliance[160] - The company has implemented various environmental protection measures, including waste gas treatment systems, which have faced operational challenges in 2022[143] - The company reported a total environmental governance expenditure of approximately 800,000 RMB in 2022, with an environmental protection tax payment of 522.45 RMB[164] - The company has successfully maintained compliance with wastewater discharge standards for COD at 25.9751 mg/L, against a limit of 100 mg/L[159] Governance and Compliance - The company maintains an independent governance structure, ensuring no interference from the controlling shareholder in decision-making processes[101] - The company emphasizes transparency in information disclosure, adhering to regulations and ensuring timely and accurate reporting[103] - The board of directors operates with a reasonable professional structure and adheres to legal and regulatory requirements[102] - The company has established a robust internal control system to enhance management and compliance[104] Future Outlook - The company plans to enhance its production capabilities by expanding its CDMO business and utilizing existing production lines to maximize capacity[87] - The company is actively pursuing internationalization, with plans for cGMP upgrades and dual submissions for major products in both China and the U.S.[45] - The company plans to enter the European market by Q3 2023, targeting a revenue contribution of 10% from this region[151] - The company expects a revenue growth of 15% for the next fiscal year, projecting a target revenue of 1.725 billion CNY[151]

Financial Performance - The company's revenue for Q1 2023 was ¥176,056,130.03, a decrease of 2.95% compared to ¥181,402,884.35 in the same period last year[3] - Net profit attributable to shareholders decreased by 61.69% to ¥1,278,629.96 from ¥3,338,005.22 year-on-year[3] - Basic and diluted earnings per share fell by 60.53% to ¥0.0015 from ¥0.0038 in the same period last year[3] - Net profit for Q1 2023 was CNY 8,743,250.95, a decline of 28.5% from CNY 12,166,960.10 in Q1 2022[15] - The company reported a decrease in basic and diluted earnings per share to CNY 0.0015 from CNY 0.0038 in the previous year[16] Cash Flow - The net cash flow from operating activities increased significantly by 295.27% to ¥13,623,933.97 compared to ¥3,446,754.01 in the previous year[3] - Cash flow from operating activities increased to CNY 202,370,713.36 in Q1 2023, compared to CNY 186,693,029.70 in Q1 2022, representing an increase of 8.9%[17] - The net cash flow from operating activities for Q1 2023 was ¥13,623,933.97, an increase from ¥3,446,754.01 in Q1 2022, representing a significant improvement[18] - Total cash inflow from operating activities amounted to ¥207,907,529.55, compared to ¥195,527,717.11 in the same period last year[18] - The company paid ¥30,851,865.05 in taxes during the quarter, compared to ¥8,052,906.25 in the previous year, reflecting increased tax obligations[18] - Cash received from other operating activities was ¥5,536,816.19, showing a decrease from ¥8,834,687.41 year-over-year[18] - The company incurred cash payments to employees totaling ¥36,266,206.23, a decrease from ¥39,982,668.05 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,474,206,115.16, reflecting a slight increase of 0.39% from ¥1,468,474,402.63 at the end of the previous year[3] - The company’s total assets amounted to CNY 1,474,206,115.16, a slight increase from CNY 1,468,474,402.63 at the end of the previous quarter[13] - Total liabilities were reported at CNY 1,251,235,538.73, a decrease from CNY 1,253,645,942.02 in the previous quarter[13] - The company’s equity attributable to shareholders increased to CNY 178,899,747.20 from CNY 177,927,696.16 in the previous quarter[13] Operating Costs and Income - Total operating costs for Q1 2023 were CNY 168,775,870.62, down from CNY 170,714,929.26 in the same period last year, reflecting a reduction of 1.1%[14] - The company reported a significant decrease in other income by 88.90%, primarily due to lower government subsidies compared to the previous year[6] Research and Development - Research and development expenditures capitalized increased by 30.14%, reflecting the company's commitment to innovation[6] - Research and development expenses for Q1 2023 were CNY 5,099,494.09, slightly up from CNY 4,875,944.05 in Q1 2022[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 73,540[7] Cash Flow from Investing and Financing Activities - The net cash flow from investing activities was -¥5,259,594.09, a decrease from ¥84,691,218.51 in Q1 2022, indicating a shift in investment strategy[19] - Cash inflow from financing activities totaled ¥138,000,000.00, while cash outflow was ¥147,210,453.05, resulting in a net cash flow of -¥9,210,453.05[19] - The company’s cash flow from financing activities included cash received from borrowings of ¥138,000,000.00, indicating reliance on debt financing[19] - The ending balance of cash and cash equivalents was ¥180,549,539.74, down from ¥151,688,057.20 in Q1 2022[19] - The company reported cash inflow from the disposal of fixed assets and other long-term assets of ¥1,129,800.00, compared to ¥900,800.00 in the previous year[18]

湖南景峰医药股份有限公司投资者关系活动记录表 编号：1 | --- | --- | --- | |----------------|------------------------------------|-----------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 1. 中欧基金管理有限公司 葛兰 | | | 人员姓名 | 2. 华富基金管理有限公司 傅晟 | | | | 3. | 浙江浙商证券资产管理有限公司 戴颖 | | | 4. 源实资管 江琦 | | | | 5. | 西南证券股份有限公司 施跃 陈铁林 | | | 6. 域秀资本 池陈森 | | | | 7. 兴业全球基金管理有限公司 杨世进 | | | | 8 | ．上海盈象资产管理有限公司 张袁魁 | | | 9. 长信基金 张子乔 | | | | ...

编号：20170522 证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 长城证券股份有限公司 金融研究所 赵浩然 | | 人员姓名 | | | | 时间 | 2017 年 5 月 22 | 日星期一上午 9:30-11:00 | | 地点 | 上海浦东新区张杨路 | 500 号 30 层 | | 上市公司接待人 员姓名 | | 董事会秘书 欧阳艳丽、研发中心总经理 马鹰军 | | 投资者关系活动 ...

证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 编号：20191015 | --- | --- | |----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000908 证券简称：景峰医药 编号：20190906 | --- | --- | |----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | ■特定对象调研 | | | 参与单位名称 汇添富基金管理股份有限公司 | | 时间 2019 | 年 9 月 6 日 14:00-16:00 | | 地点 | 上海市浦东新区张杨路 500 号华润时代广场 30 楼会议室 | | 上 市 公 司 接 待 人员 | 李 杰 湖南景峰医药股份有限公司研发中心副总经理 | | | 1 、公司原有销售模式是什么？这次营销改革期望改成什么样？ | | | 答：公司原有模式为自营、代理和外包，未来希望加大自营比 例，加大三终端的覆盖。目前公司将终端市场 ...

证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 编号：20190523 | --- | --- | |------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | ■特定对象调研 | | 参与单位名称 | 1 、华安证券股份有限公司 2 、贝莱德投资管理（上海）有限公司 | | 时间 2019 | 年 5 月 23 日 13:30-16:00 | | | 地点 上海市宝山区罗新路 50 号 | | 上 市 公 司 接 待 人员 | ...

证券代码：000908 证券简称：景峰医药 湖南景峰医药股份有限公司投资者关系活动记录表 编号：20190519 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...